EPS創健科技(03860.HK)擬出售EPS Innovative Medicine（Hong Kong）全部股權
格隆匯2月19日丨EPS創健科技(03860.HK)公吿，於2025年2月19日，公司（作為賣方）與買方（為公司的控股股東）訂立買賣協議，據此，公司有條件同意出售而買方有條件同意收購目標公司EPS Innovative Medicine（Hong Kong）Limited的全部已發行股本，代價為1.00日圓。
根據買賣協議，公司亦有條件同意出售或促使出售而買方有條件同意收購銷售貸款（即目標公司與EPD HK於本公吿日期結欠公司、創健商貿及EPS Medical按面值計算合共約61,365,000港元的若干貸款，代價為約61,365,000港元。
目標公司為一家在香港註冊成立的有限責任公司，主要業務為投資控股下文所述目標集團的其他成員公司，以及持有一間根據日本法律成立的有限合夥企業的若干有限合夥單位。
在近期對集團的投資組合進行評估時，管理層發現目標集團的業務及財務表現不如預期令人滿意。於截至2024年12月31日止年度，目標集團錄得未經審核虧損約51.9百萬港元。表現欠佳乃因多重因素所致，包括經濟挑戰持續不斷及研發工作遙遙無期。此外，目標集團成員公司正在進行的運營及研發活動估計可能會耗費額外及持續的成本、時間及資源，以向市場推出生物科技產品（其面市經已延期）。此情形使得集團需要對目標集團投入額外的時間及資源，且無法保證可獲得回報，令財務前景更趨複雜。
由於集團的管理重心現為可盈利的核心業務，並且認為目標集團的業務為長期預先投資型，與其現時的管理重心並不一致，故而管理層尋求出售目標集團，以降低目標集團因財務表現不理想而對集團整體盈利能力造成不利的財務影響。因此，出於對集團利益的考慮，買方（作為公司的控股股東）有條件同意推進該策略性舉措，透過收購銷售股份使集團撤出對目標集團的投資，從而令集團能夠專注於提升其在更具盈利能力的核心業務分部的業績表現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
